{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T16:51:07Z","timestamp":1785775867668,"version":"3.56.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2009,6,26]],"date-time":"2009-06-26T00:00:00Z","timestamp":1245974400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1007\/s10620-009-0864-7","type":"journal-article","created":{"date-parts":[[2009,6,25]],"date-time":"2009-06-25T16:42:21Z","timestamp":1245948141000},"page":"338-345","source":"Crossref","is-referenced-by-count":8,"title":["Rabeprazole 20\u00a0mg for Erosive Esophagitis-Associated Symptoms in a Large, Community-Based Study: Additional Results"],"prefix":"10.1007","volume":"55","author":[{"given":"Alan","family":"Cutler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byron","family":"DeLemos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,6,26]]},"reference":[{"issue":"Suppl 4a","key":"864_CR1","doi-asserted-by":"crossref","first-page":"99S","DOI":"10.1016\/S0002-9343(99)00347-2","volume":"108","author":"JF Johanson","year":"2000","unstructured":"Johanson JF. Epidemiology of esophageal and supraesophageal reflux injuries. Am J Med. 2000;108(Suppl 4a):99S\u2013103S. doi: 10.1016\/S0002-9343(99)00347-2 .","journal-title":"Am J Med"},{"issue":"5","key":"864_CR2","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/S0016-5085(97)70025-8","volume":"112","author":"GR Locke III","year":"1997","unstructured":"Locke GR III, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ III. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology. 1997;112(5):1448\u20131456. doi: 10.1016\/S0016-5085(97)70025-8 .","journal-title":"Gastroenterology"},{"issue":"8","key":"864_CR3","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1111\/j.1572-0241.2000.02235.x","volume":"95","author":"MA Eloubeidi","year":"2000","unstructured":"Eloubeidi MA, Provenzale D. Health-related quality of life and severity of symptoms in patients with Barrett\u2019s esophagus and gastroesophageal reflux disease patients without Barrett\u2019s esophagus. Am J Gastroenterol. 2000;95(8):1881\u20131887. doi: 10.1111\/j.1572-0241.2000.02235.x .","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"864_CR4","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2165\/00003495-199549050-00005","volume":"49","author":"EC Klinkenberg-Knol","year":"1995","unstructured":"Klinkenberg-Knol EC, Festen HP, Meuwissen SG. Pharmacological management of gastro-oesophageal reflux disease. Drugs. 1995;49(5):695\u2013710. doi: 10.2165\/00003495-199549050-00005 .","journal-title":"Drugs"},{"issue":"1","key":"864_CR5","first-page":"61","volume":"50","author":"CA Flynn","year":"2001","unstructured":"Flynn CA. The evaluation and treatment of adults with gastroesophageal reflux disease. J Fam Pract. 2001;50(1):61\u201363.","journal-title":"J Fam Pract"},{"issue":"2","key":"864_CR6","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1572-0241.2001.03511.x","volume":"96","author":"R Fass","year":"2001","unstructured":"Fass R, Fennerty MB, Vakil N. Nonerosive reflux disease\u2014current concepts and dilemmas. Am J Gastroenterol. 2001;96(2):303\u2013314.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"864_CR7","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/j.1572-0241.2004.30488.x","volume":"99","author":"N Chiba","year":"2004","unstructured":"Chiba N. Treat the patients\u2019 main dyspepsia complaint, not the ROME criteria. Am J Gastroenterol. 2004;99(6):1059\u20131062. doi: 10.1111\/j.1572-0241.2004.30488.x .","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"864_CR8","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1053\/gast.1997.v112.pm9178669","volume":"112","author":"N Chiba","year":"1997","unstructured":"Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997;112(6):1798\u20131810. doi: 10.1053\/gast.1997.v112.pm9178669 .","journal-title":"Gastroenterology"},{"issue":"12","key":"864_CR9","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1046\/j.1365-2036.2003.01496.x","volume":"17","author":"D Pantoflickova","year":"2003","unstructured":"Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum AL. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther. 2003;17(12):1507\u20131514. doi: 10.1046\/j.1365-2036.2003.01496.x .","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"864_CR10","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1046\/j.1365-2036.1998.00418.x","volume":"12","author":"MP Williams","year":"1998","unstructured":"Williams MP, Sercombe J, Hamilton MI, Pounder RE. A placebo-controlled trial to assess the effects of 8\u00a0days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther. 1998;12(11):1079\u20131089. doi: 10.1046\/j.1365-2036.1998.00418.x .","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"864_CR11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1046\/j.1365-2036.1999.00438.x","volume":"13","author":"CP Dekkers","year":"1999","unstructured":"Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ. Double-blind comparison [correction of double-blind, placebo-controlled comparison] of rabeprazole 20\u00a0mg vs. omeprazole 20\u00a0mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European rabeprazole study group. Aliment Pharmacol Ther. 1999;13(1):49\u201357. doi: 10.1046\/j.1365-2036.1999.00438.x .","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"864_CR12","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1080\/003655200453566","volume":"35","author":"JC Delchier","year":"2000","unstructured":"Delchier JC, Cohen G, Humphries TJ. Rabeprazole, 20\u00a0mg once daily or 10\u00a0mg twice daily, is equivalent to omeprazole, 20\u00a0mg once daily, in the healing of erosive gastrooesophageal reflux disease. Scand J Gastroenterol. 2000;35(12):1245\u20131250. doi: 10.1080\/003655200453566 .","journal-title":"Scand J Gastroenterol"},{"issue":"5","key":"864_CR13","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1023\/A:1005548318996","volume":"45","author":"B Thjodleifsson","year":"2000","unstructured":"Thjodleifsson B, Beker JA, Dekkers C, Bjaaland T, Finnegan V, Humphries TJ. Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European rabeprazole study group. Dig Dis Sci. 2000;45(5):845\u2013853. doi: 10.1023\/A:1005548318996 .","journal-title":"Dig Dis Sci"},{"issue":"3","key":"864_CR14","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1365-2036.2005.02555.x","volume":"22","author":"A Caos","year":"2005","unstructured":"Caos A, Breiter J, Perdomo C, Barth J. Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20\u00a0mg vs. placebo: results of a 5-year study in the United States. Aliment Pharmacol Ther. 2005;22(3):193\u2013202. doi: 10.1111\/j.1365-2036.2005.02555.x .","journal-title":"Aliment Pharmacol Ther"},{"key":"864_CR15","doi-asserted-by":"crossref","unstructured":"Jacobson BC, DeLemos B, Sun Y, Xiang J, LoCocos J, Li H, et al. PPI efficacy in overweight\/obese patients with erosive GERD: rabeprazole (RAB) 20\u00a0mg vs. omeprazole (OME) 20\u00a0mg. 2007 [abstract, submitted to American College of Gastroenterology; Philadelphia October 12\u201317].","DOI":"10.14309\/00000434-200709002-00089"},{"issue":"Suppl 3","key":"864_CR16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1046\/j.1365-2036.1999.00022.x","volume":"13","author":"T Ishizaki","year":"1999","unstructured":"Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors\u2014emphasis on rabeprazole. Aliment Pharmacol Ther. 1999;13(Suppl 3):27\u201336. doi: 10.1046\/j.1365-2036.1999.00022.x .","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"864_CR17","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1365-2036.2002.01181.x","volume":"16","author":"M Robinson","year":"2002","unstructured":"Robinson M, Fitzgerald S, Hegedus R, Murthy A, Jokubaitis L. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis. Aliment Pharmacol Ther. 2002;16(3):445\u2013454. doi: 10.1046\/j.1365-2036.2002.01181.x .","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"864_CR18","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1046\/j.1365-2036.2002.01207.x","volume":"16","author":"G Holtmann","year":"2002","unstructured":"Holtmann G, Bytzer P, Metz M, Loeffler V, Blum AL. A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2002;16(3):479\u2013485. doi: 10.1046\/j.1365-2036.2002.01207.x .","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"864_CR19","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1111\/j.1572-0241.2002.05769.x","volume":"97","author":"P Miner Jr","year":"2002","unstructured":"Miner P Jr, Orr W, Filippone J, Jokubaitis L, Sloan S. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol. 2002;97(6):1332\u20131339. doi: 10.1111\/j.1572-0241.2002.05769.x .","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"864_CR20","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1007\/s10620-005-3000-3","volume":"50","author":"PJ Kahrilas","year":"2005","unstructured":"Kahrilas PJ, Miner P, Johanson J, Mao L, Jokubaitis L, Sloan S. Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease. Dig Dis Sci. 2005;50(11):2009\u20132018. doi: 10.1007\/s10620-005-3000-3 .","journal-title":"Dig Dis Sci"},{"issue":"1","key":"864_CR21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00063198-199901000-00011","volume":"5","author":"PE Patterson","year":"1999","unstructured":"Patterson PE, Harding SM. Gastroesophageal reflux disorders and asthma. Curr Opin Pulm Med. 1999;5(1):63\u201367. doi: 10.1097\/00063198-199901000-00011 .","journal-title":"Curr Opin Pulm Med"},{"issue":"1","key":"864_CR22","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3109\/00365529108996486","volume":"26","author":"M Ruth","year":"1991","unstructured":"Ruth M, Mansson I, Sandberg N. The prevalence of symptoms suggestive of esophageal disorders. Scand J Gastroenterol. 1991;26(1):73\u201381. doi: 10.3109\/00365529108996486 .","journal-title":"Scand J Gastroenterol"},{"issue":"11","key":"864_CR23","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1023\/A:1020532714664","volume":"47","author":"JF Johanson","year":"2002","unstructured":"Johanson JF, Siddique R, Damiano AM, Jokubaitis L, Murthy A, Bhattacharjya A. Rabeprazole improves health-related quality of life in patients with erosive gastroesophageal reflux disease. Dig Dis Sci. 2002;47(11):2574\u20132578. doi: 10.1023\/A:1020532714664 .","journal-title":"Dig Dis Sci"},{"issue":"4","key":"864_CR24","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1023\/A:1022812103923","volume":"48","author":"A Damiano","year":"2003","unstructured":"Damiano A, Siddique R, Xu X, Johanson J, Sloan S. Reductions in symptom distress reported by patients with moderately severe, nonerosive gastroesophageal reflux disease treated with rabeprazole. Dig Dis Sci. 2003;48(4):657\u2013662. doi: 10.1023\/A:1022812103923 .","journal-title":"Dig Dis Sci"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-009-0864-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-009-0864-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-009-0864-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T21:02:24Z","timestamp":1633640544000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-009-0864-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,26]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["864"],"URL":"https:\/\/doi.org\/10.1007\/s10620-009-0864-7","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6,26]]}}}